Drugs / HS-10374
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07181343 | May → Jun 2025 | psoriasis | Hansoh BioMedical R&D Company | Completed | No outcome recorded |
| Phase 1 | NCT06033742 | Nov 2021 → Mar 2023 | psoriasis | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06926582 | Apr 2025 → Jul 2026 overdue | psoriasis | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06176508 | Feb 2024 → Apr 2026 overdue | psoriatic arthritis | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 2 | NCT06077331 | Sep 2023 → Jul 2024 | psoriasis | Hansoh BioMedical R&D Company | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06672393 | Nov 2024 → Oct 2025 overdue | psoriasis | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-09-21 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA ANNOUNCES PIVOTAL PHASE 3 CLINICAL TRIAL OF HS-10374 IN THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS MET THE CO-PRIMARY ENDPOINTS hspharm.com ↗
Pivotal Phase 3 clinical trial of HS-10374 met co-primary endpoints in adults with moderate-to-severe plaque psoriasis, with both PASI 75 and sPGA 0/1 response rates significantly higher than those in the placebo group at week 16. |
| 2024-11-29 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA PRESENTS POSITIVE PHASE II CLINICAL STUDY OF HS-10374, IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AT CDA 2024 hspharm.com ↗
HS-10374 showed significant clinical efficacy versus Placebo (PBO) in terms of PASI 75 response rate and sPGA 0/1 response rate with oral doses of 6 mg QD or 12 mg QD in patients with moderate-to-severe plaque psoriasis. |
| 2024-11-29 | Hansoh BioMedical R&D Company | Results CDA 2024 | 翰森制药TYK2抑制剂HS-10374用于治疗中重度斑块状银屑病的Ⅱ期临床研究积极数据发布 hansoh.cn ↗
本次CDA大会发表的研究数据显示，当HS-10374口服剂量为6mg QD或12mg QD时，其在中重度斑块状银屑病患者中可达到显著高于安慰剂的PASI 75应答率和sPGA 0/1应答率，有效性显著. |
| 2024-10-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results EADV 2024 | HANSOH PHARMA RELEASED THE PHASE II CLINICAL STUDY DATA OF HS-10374，IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS hspharm.com ↗
The recently published clinical trial results of HS-10374 showed significant clinical efficacy versus PBO in terms of PASI 75 response rate and sPGA 0/1 response rate with oral doses of ≥6 mg in patients with moderate-to-severe plaque psoriasis. |
| 2024-10-10 | Hansoh BioMedical R&D Company | Results EADV 2024 | 翰森制药HS-10374 Ⅱ期研究数据获口头报告，用于治疗中重度斑状银屑病 hansoh.cn ↗
本 次 在EADV大 会 发 表 的 研 究 数 据 显 示，在 中 重 度 斑 块 状 银 屑 病 患 者 中，HS-10374有 效 性 显 著，整 体 安 全 性 与 其 他TYK2抑 制 剂 相 似，且 皮 肤 毒 性 风 险 较 低. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-21 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA ANNOUNCES PIVOTAL PHASE 3 CLINICAL TRIAL OF HS-10374 IN THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS MET THE CO-PRIMARY ENDPOINTS hspharm.com ↗ |
| 2026-09-21 | Hansoh BioMedical R&D Company | 翰森制药 | HS-10374（TYK2抑制剂）治疗成人中重度斑块状银屑病关键III期临床研究达到共同主要终点 hansoh.cn ↗ |
| 2024-11-29 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA PRESENTS POSITIVE PHASE II CLINICAL STUDY OF HS-10374, IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AT CDA 2024 hspharm.com ↗ |
| 2024-11-29 | Hansoh BioMedical R&D Company | CDA 2024 | 翰森制药TYK2抑制剂HS-10374用于治疗中重度斑块状银屑病的Ⅱ期临床研究积极数据发布 hansoh.cn ↗ |
| 2024-10-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | EADV 2024 | HANSOH PHARMA RELEASED THE PHASE II CLINICAL STUDY DATA OF HS-10374，IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS hspharm.com ↗ |
| 2024-10-10 | Hansoh BioMedical R&D Company | EADV 2024 | 翰森制药HS-10374 Ⅱ期研究数据获口头报告，用于治疗中重度斑状银屑病 hansoh.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10374 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06033742 ↗ |
| Route | Oral | “Single or multiple dosing of HS-10374 orally in a fasting state” NCT06033742 ↗ |